| Previous close | N/A |
| YTD return | N/A |
| Expense ratio (net) | N/A |
| Category | N/A |
| Last cap gain | N/A |
| Morningstar rating | N/A |
| Morningstar risk rating | N/A |
| Sustainability rating | N/A |
| Net assets | N/A |
| Beta (5Y monthly) | N/A |
| Yield | N/A |
| 5y average return | N/A |
| Holdings turnover | N/A |
| Last dividend | N/A |
| Average for category | N/A |
| Inception date | N/A |
GlobeNewswireBurning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) on May 30, 2024, informing the Company that it has regained compliance with the m
- GlobeNewswire
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion dia
GlobeNewswireBurning Rock Reports First Quarter 2024 Financial Results
GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Editi
